NASDAQ:RCKTRocket Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Rocket Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $27.44 +0.26 (+0.96 %) (As of 08/14/2020 09:37 AM ET) Add Compare Share Today's Range$26.72Now: $27.44▼$27.7250-Day Range$20.50MA: $23.63▼$27.1852-Week Range$9.01Now: $27.44▼$29.14Volume371,200 shsAverage Volume424,408 shsMarket Capitalization$1.51 billionP/E RatioN/ADividend YieldN/ABeta2.12 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingRocket Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.33, Rocket Pharmaceuticals has a potential upside of 36.1% from its current price of $27.44.Amount of Analyst CoverageRocket Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.9 Community Rank Outperform VotesRocket Pharmaceuticals has received 309 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRocket Pharmaceuticals has received 223 “underperform” votes. (Add your “underperform” vote.)Community SentimentRocket Pharmaceuticals has received 58.08% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Rocket Pharmaceuticals and other stocks. Vote “Outperform” if you believe RCKT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RCKT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders38.80% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.70% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($1.93) to ($1.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -16.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -16.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 4.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.01 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RCKT Previous Symbol CUSIPN/A CIK1281895 Webwww.rocketpharma.com Phone646-440-9100Debt Debt-to-Equity Ratio0.23 Current Ratio13.25 Quick Ratio13.25Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.10 per share Price / Book4.50Profitability EPS (Most Recent Fiscal Year)($1.58) Net Income$-77,270,000.00 Net MarginsN/A Return on Equity-32.30% Return on Assets-25.51%Miscellaneous Employees33 Outstanding Shares55,188,000Market Cap$1.51 billion Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $27.44 +0.26 (+0.96 %) (As of 08/14/2020 09:37 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive RCKT News and Ratings via Email Sign-up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter. Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions How has Rocket Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)? Rocket Pharmaceuticals' stock was trading at $15.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RCKT shares have increased by 71.6% and is now trading at $27.44. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Rocket Pharmaceuticals? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Rocket Pharmaceuticals. When is Rocket Pharmaceuticals' next earnings date? Rocket Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Rocket Pharmaceuticals. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals Inc (NASDAQ:RCKT) announced its quarterly earnings data on Wednesday, August, 5th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.05. View Rocket Pharmaceuticals' earnings history. What price target have analysts set for RCKT? 9 brokers have issued twelve-month target prices for Rocket Pharmaceuticals' shares. Their forecasts range from $33.00 to $43.00. On average, they anticipate Rocket Pharmaceuticals' stock price to reach $37.33 in the next year. This suggests a possible upside of 36.1% from the stock's current price. View analysts' price targets for Rocket Pharmaceuticals. Has Rocket Pharmaceuticals been receiving favorable news coverage? News stories about RCKT stock have been trending positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Rocket Pharmaceuticals earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news about Rocket Pharmaceuticals. Who are some of Rocket Pharmaceuticals' key competitors? Some companies that are related to Rocket Pharmaceuticals include Mirati Therapeutics (MRTX), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), Zai Lab (ZLAB), HUTCHISON CHINA/S (HCM), Schrodinger (SDGR), Allakos (ALLK), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), FibroGen (FGEN), Legend Biotech (LEGN), HYPERA S A/S (HYPMY) and Amicus Therapeutics (FOLD). View all competitors. What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Amarin (AMRN), Micron Technology (MU), Sorrento Therapeutics (SRNE), Alibaba Group (BABA), Energy Transfer LP Unit (ET), VBI Vaccines (VBIV) and Crispr Therapeutics (CRSP). Who are Rocket Pharmaceuticals' key executives? Rocket Pharmaceuticals' management team includes the following people: Mr. Gaurav Shah, CEO, Pres & Director (Age 44)Mr. John C. Militello, Controller (Age 46)Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA, COO & Head of Devel. (Age 39)Dr. Claudine Prowse Ph.D., Sr. VP of Corp. Strategy & IROMr. Jonathan Schwartz, Chief Medical Officer (Age 55) What is Rocket Pharmaceuticals' stock symbol? Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT." Who are Rocket Pharmaceuticals' major shareholders? Rocket Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (1.81%), Goldman Sachs Group Inc. (1.20%), Assenagon Asset Management S.A. (0.89%), Tekla Capital Management LLC (0.52%), Alps Advisors Inc. (0.14%) and Swiss National Bank (0.12%). Company insiders that own Rocket Pharmaceuticals stock include David P Southwell, Gaurav Shah, Kinnari Patel and Rtw Investments, Lp. View institutional ownership trends for Rocket Pharmaceuticals. Which institutional investors are selling Rocket Pharmaceuticals stock? RCKT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Goldman Sachs Group Inc., UBS Group AG, Alps Advisors Inc., Torray LLC, Algert Global LLC, Comerica Bank, and Mitsubishi UFJ Kokusai Asset Management Co. Ltd.. View insider buying and selling activity for Rocket Pharmaceuticals. Which institutional investors are buying Rocket Pharmaceuticals stock? RCKT stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Tekla Capital Management LLC, Marshall Wace North America L.P., Monarch Partners Asset Management LLC, Rafferty Asset Management LLC, State Board of Administration of Florida Retirement System, Quantitative Systematic Strategies LLC, and ProShare Advisors LLC. Company insiders that have bought Rocket Pharmaceuticals stock in the last two years include Kinnari Patel, and Rtw Investments, Lp. View insider buying and selling activity for Rocket Pharmaceuticals. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Rocket Pharmaceuticals' stock price today? One share of RCKT stock can currently be purchased for approximately $27.44. How big of a company is Rocket Pharmaceuticals? Rocket Pharmaceuticals has a market capitalization of $1.51 billion. The biotechnology company earns $-77,270,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Rocket Pharmaceuticals employs 33 workers across the globe. What is Rocket Pharmaceuticals' official website? The official website for Rocket Pharmaceuticals is www.rocketpharma.com. How can I contact Rocket Pharmaceuticals? Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected] This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
